MyWay Digital Health Secures £3m to Scale NHS Diabetes Tool

Key Takeaways

• £3m funding secured from Foresight Group.
• Platform used across multiple NHS regions.
• AI-enabled products to be developed.
• Expansion into global markets planned.
• Dr Umang Patel joins as non‑executive chair.

Summary

Edinburgh‑based MyWay Digital Health has raised £3 million from Foresight Group to scale its clinically validated MyWay Diabetes platform, already deployed across several NHS regions. The funding will accelerate growth, broaden the product suite and fund AI‑enabled predictive analytics and personalized care pathways. The round also brings Dr Umang Patel, Microsoft’s EMEA chief clinical information officer, onto the board as non‑executive chair, supporting domestic and international expansion.

Pulse Analysis

The NHS faces a growing diabetes burden, with chronic disease management consuming a sizable share of healthcare resources. Digital self‑management tools like MyWay Diabetes are increasingly adopted to empower patients, improve adherence, and provide clinicians with real‑time data visualisation. By integrating directly with NHS electronic health records, the platform delivers personalised education and actionable insights, helping to reduce hospital admissions and streamline routine monitoring.

The £3 million injection from Foresight Group marks a pivotal moment for MyWay Digital Health. Beyond the capital boost, the partnership brings strategic expertise through Dr Umang Patel, whose experience at Microsoft adds credibility to the company’s AI ambitions. The funding will underpin the development of predictive analytics and AI‑driven care pathways, extending the product suite to cover cardiovascular health, hypertension, and weight management. This expansion aligns with the broader push for data‑driven, preventative care models across the UK and abroad.

For investors and healthcare providers, MyWay’s trajectory illustrates the convergence of clinical validation, technology, and private‑equity support in scaling digital health solutions. As the company eyes international markets, its success could set a benchmark for how digital therapeutics achieve cost‑effectiveness while enhancing patient outcomes. The rollout of AI‑enabled features promises to further reduce clinician workload, a critical factor as the NHS seeks sustainable solutions to chronic disease pressures. Confidence in MyWay’s model may spur additional capital flows into the sector, accelerating innovation across the health‑tech landscape.